HUP0102014A2 - Humán Protein C polipeptid - Google Patents

Humán Protein C polipeptid

Info

Publication number
HUP0102014A2
HUP0102014A2 HU0102014A HUP0102014A HUP0102014A2 HU P0102014 A2 HUP0102014 A2 HU P0102014A2 HU 0102014 A HU0102014 A HU 0102014A HU P0102014 A HUP0102014 A HU P0102014A HU P0102014 A2 HUP0102014 A2 HU P0102014A2
Authority
HU
Hungary
Prior art keywords
polypeptide
human protein
isolated
disorders
thrombosis
Prior art date
Application number
HU0102014A
Other languages
English (en)
Inventor
Lihua Huang
Ralph Meridith Riggin
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0102014A2 publication Critical patent/HUP0102014A2/hu
Publication of HUP0102014A3 publication Critical patent/HUP0102014A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát csonkított nehéz lánccal rendelkező izolált humánProtein C polipeptid képezi. Az izolált polipeptid megtartja a vad-típusú humán Protein C biológiai aktivitását. Ez a polipeptid jólhasználható a vaszkuláris elzáródási rendellenességek,hiperkoagulálódási állapotok, trombotikus rendellenességek éstrombózisra hajlamosító kóros állapotok kezelésében. Ó
HU0102014A 1998-06-01 1999-06-01 Human protein c polypeptide HUP0102014A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8758598P 1998-06-01 1998-06-01
PCT/US1999/011969 WO1999063070A1 (en) 1998-06-01 1999-06-01 Human protein c polypeptide

Publications (2)

Publication Number Publication Date
HUP0102014A2 true HUP0102014A2 (hu) 2001-10-28
HUP0102014A3 HUP0102014A3 (en) 2003-09-29

Family

ID=22206075

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102014A HUP0102014A3 (en) 1998-06-01 1999-06-01 Human protein c polypeptide

Country Status (25)

Country Link
US (1) US20040038288A1 (hu)
EP (1) EP1084235A4 (hu)
JP (1) JP2002517191A (hu)
KR (1) KR20010043941A (hu)
CN (1) CN1303428A (hu)
AR (1) AR020082A1 (hu)
AU (1) AU4409399A (hu)
BR (1) BR9910858A (hu)
CA (1) CA2330171A1 (hu)
CO (1) CO5070672A1 (hu)
DZ (1) DZ2803A1 (hu)
EA (1) EA200001254A1 (hu)
HR (1) HRP20000826A2 (hu)
HU (1) HUP0102014A3 (hu)
ID (1) ID27282A (hu)
IL (1) IL139595A0 (hu)
NO (1) NO20006091L (hu)
NZ (1) NZ507982A (hu)
PE (1) PE20000561A1 (hu)
PL (1) PL344349A1 (hu)
SK (1) SK17502000A3 (hu)
SV (1) SV1999000067A (hu)
TR (1) TR200003552T2 (hu)
WO (1) WO1999063070A1 (hu)
ZA (1) ZA200006647B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821884B2 (en) * 2004-07-27 2014-09-02 The Regents Of The University Of California Compositions and methods using MD-2 mutants and chimeric proteins
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
ATE163048T1 (de) * 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
JPH0564588A (ja) * 1991-08-14 1993-03-19 Teijin Ltd 短い重鎖を有するヒトプロテインｃおよび活性化ヒトプロテインｃ

Also Published As

Publication number Publication date
EA200001254A1 (ru) 2001-06-25
HRP20000826A2 (en) 2001-10-31
CN1303428A (zh) 2001-07-11
JP2002517191A (ja) 2002-06-18
US20040038288A1 (en) 2004-02-26
WO1999063070A1 (en) 1999-12-09
PE20000561A1 (es) 2000-07-22
EP1084235A1 (en) 2001-03-21
DZ2803A1 (fr) 2003-12-01
AU4409399A (en) 1999-12-20
ZA200006647B (en) 2001-11-15
NZ507982A (en) 2004-01-30
CO5070672A1 (es) 2001-08-28
ID27282A (id) 2001-03-22
CA2330171A1 (en) 1999-12-09
KR20010043941A (ko) 2001-05-25
SV1999000067A (es) 2000-07-06
IL139595A0 (en) 2002-02-10
HUP0102014A3 (en) 2003-09-29
EP1084235A4 (en) 2002-03-27
TR200003552T2 (tr) 2001-05-21
PL344349A1 (en) 2001-11-05
AR020082A1 (es) 2002-04-10
NO20006091D0 (no) 2000-11-30
NO20006091L (no) 2001-01-31
BR9910858A (pt) 2001-03-06
SK17502000A3 (sk) 2001-09-11

Similar Documents

Publication Publication Date Title
EP1007089A4 (en) ANTI-COAGULATING AGENTS FOR USE IN THROMBOSIS TREATMENTS
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
CY1108580T1 (el) Αυτοανοσες παθησεις και ελλειμματα nadph οξειδασης
DE69932845D1 (de) Methoden zur quantifizierung von hla-dr und cd11b
EE9800306A (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
SE8902532L (sv) Bestaemning av plasmaproteiner
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
ATE183243T1 (de) Methoden zur bestimmung der blutplaettchenfunktion
WO1996024650A3 (en) Cytoplasmic antiproteinase-2 and cytoplasmic antiproteinase-3 and coding sequences
PT948604E (pt) Produtos e metodos relacionados com pyk2
HUP0102014A2 (hu) Humán Protein C polipeptid
EP0960117A4 (en) ON FIBROBLASTS GROWTH FACTOR HOMOLOGICAL FACTORS (FHFs) AND METHOD OF APPLICATION
ATE329015T1 (de) Enzyme mit s-adenosyl-l-homocystein-hydrolase- ähnlicher aktivität.
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
DE60108076D1 (de) Protein c derivate
DE69535232D1 (de) DNA-SEQUENZEN, DIE FÜR DIE MENSCHLICHE PROTEINE Tx UND Ty KODIEREN, DIE ICE GLEICHEN
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
DE68920757D1 (de) Lysyl-Oxidase-Inhibitoren.
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE59813914D1 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
ATE312914T1 (de) Rdgb-proteine
DE69836278D1 (de) Allele formen von menschlichem stat3
ATE222121T1 (de) Verwendung von bromelainproteasen zur hemmung der blutgerinnung
ATE269356T1 (de) Mutierte gewebefaktor-inhibitor (tfpi), dna sequenz davon und verwendung zur erkennung von thrombotischen erkrankungen
ATA27696A (de) Benutzung der menschlichen megakaryozytenartigen zellinie dami zur identifikation und bestimmung von substanzen zur hemmung der enzymatischen aktivität des enzyms cyclooxygenase-1